Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study
Fowler NH et al. Lenalidomide and rituximab for untreated indolent lymphoma: Final results of a Phase II study. Proc ASH 2012; Abstract 901.
Dr Cheson is Professor of Medicine, Deputy Chief of the Division of Hematology-Oncology and Head of Hematology at the Georgetown University Hospital Lombardi Comprehensive Cancer Center in Washington, DC.
|